Monday, June 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Sell Rating on Stellus Capital Investment with Lower Price Target

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands
0
SHARES
17
VIEWS
Share on FacebookShare on Twitter

On March 6, 2024, Bryce Rowe, an analyst at B. Riley Securities, reaffirmed his Sell rating on Stellus Capital Investment (NYSE: SCM) and adjusted the price target to $12.50, down from $13. This update comes after Stellus Capital Investment was downgraded from Neutral to Sell by B. Riley, citing a changing market environment. The previous price target of $13 has been revised in light of these developments.

SCM Stock Performance Shows Interesting Movements on March 6, 2024

On March 6, 2024, SCM’s stock performance showed some interesting movements. According to data from CNN Money, SCM was trading near the bottom of its 52-week range and below its 200-day simple moving average. This indicates that the stock may be experiencing some downward pressure.

However, on that particular day, there was a slight uptick in the price of SCM shares. The stock had increased by $0.22 since the market last closed, representing a 1.73% rise. This brought the closing price of SCM shares to $12.97.

Despite this initial increase, the stock experienced a drop of $0.09 in pre-market trading. This drop may have been influenced by various factors such as market sentiment, economic indicators, or company-specific news.

SCM Stock Performance Analysis: Revenue Decline and Net Loss Raise Concerns for Investors

On March 6, 2024, SCM stock experienced a mixed performance based on the latest financial data provided by CNN Money. The company’s total revenue for the past year was $78.77 million, a decrease of 9.86% compared to the previous year. However, the total revenue for the third quarter was $27.77 million, showing an increase of 5.67% from the previous quarter.

In terms of net income, SCM reported a net income of $14.49 million for the past year, which represents a significant decrease of 56.83% compared to the previous year. The net income for the third quarter was -$2.40 million, indicating a loss for that period and a decrease of 164.6% from the previous quarter.

Earnings per share (EPS) also saw a decline for SCM stock. The EPS for the past year was $0.74, a decrease of 56.97% compared to the previous year. The EPS for the third quarter was -$0.10, showing a loss per share and a decrease of 160.07% from the previous quarter.

Overall, these financial indicators suggest that SCM stock has faced challenges in terms of revenue, net income, and earnings per share. Investors may be concerned about the company’s performance and future prospects based on these figures. It is important for investors to closely monitor SCM’s financial performance and any updates from the company to make informed decisions about their investments in the stock.

Tags: SCM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Market Today (1)

Harvard Bioscience Inc Unveils CuttingEdge Product Advancements for Research at SOT Conference

The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

BTIG Analyst Gray Powell Optimistic about HashiCorps Future Growth

Groundbreaking Clinical Study Shows Effectiveness of AVIM Therapy in Hypertensive Pacemaker Patients

Recommended

MP Materials Stock

Rare Earth Miner MP Materials Surges as Trade Tensions Escalate

8 months ago
The Trade Desk Stock

The Trade Desk’s Puzzling Market Disconnect

7 months ago
Delta Air Lines Stock

Delta Air Lines Soars on Strong Earnings and Upbeat Forecast

8 months ago
Phibro Animal Health Stock

Phibro Animal Health Exceeds Projections with Strong Quarterly Performance

9 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bayer’s Technical Battle at the 200-Day Line Gets Reinforcement from Agriculture AI and Kidney Drug Progress

Dividend-Heavy VanEck ETF Puts Its Money on Financials and Energy as Europe Dominates the Portfolio

Siemens Energy: AI Data Centers Propel Record Backlog, but Profit-Taking Mutes Buyback Impact

German Union Boss Demands Mandatory Company Pensions as Political Rifts Widen

D-Wave Quantum: A Fortune 100 Bet and a University Sale — But the Stock’s Next Move Hinges on a Cent-Wide Support Line

Germany’s Federal Job Board Lists 24,000 Remote Positions as Hybrid Work Expands Beyond Office Roles

Trending

AMD Stock
Market Commentary

AMD Stock: Short Interest Jumps 24% as Fundamentals and Analyst Targets Collide After Sector Rout

by SiterGedge
June 8, 2026
0

The AMD share price clawed back 2.24 percent to €413.60 on Monday, offering a modest reprieve after...

Palantir Stock

New Cloud and Construction Clients Can’t Lift Palantir Past the 50-Day Line

June 8, 2026
Nvidia Stock

Nvidia’s CEO Calls the Dip a ‘Discount’ as New PC Chip Takes Aim at Apple’s Turf

June 8, 2026
Bayer Stock

Bayer’s Technical Battle at the 200-Day Line Gets Reinforcement from Agriculture AI and Kidney Drug Progress

June 8, 2026
VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock

Dividend-Heavy VanEck ETF Puts Its Money on Financials and Energy as Europe Dominates the Portfolio

June 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • AMD Stock: Short Interest Jumps 24% as Fundamentals and Analyst Targets Collide After Sector Rout
  • New Cloud and Construction Clients Can’t Lift Palantir Past the 50-Day Line
  • Nvidia’s CEO Calls the Dip a ‘Discount’ as New PC Chip Takes Aim at Apple’s Turf

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com